Filing Flows › C4 Therapeutics (CCCC) › Q2 2026 › vs Q1 2026
C4 Therapeutics (CCCC) Q2 2026 vs Q1 2026 (quarter over quarter)
C4 Therapeutics's revenue rose $489K (+8%) from $6.2M in Q1 2026 to $6.6M in Q2 2026.
C4 Therapeutics, Q2 2026: revenue $6.6M (+3% year over year), operating margin -397.9%, net loss $23.6M, operating cash flow −$1.6M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $6.6M | $6.2M | $489K | +8% |
| Other income, net | $2.8M | $2.7M | $132K | +5% |
| Net loss | $23.6M | $25.1M | −$1.5M | -6% |
| Costs & expenses | $33.1M | $33.9M | −$873K | -3% |
| Operating costs | $33.1M | $33.9M | −$873K | -3% |
| Research & development | $24.5M | $24.6M | −$135K | -0.5% |
| General & admin | $8.6M | $9.3M | −$738K | -8% |
| Operating cash sources | $23.6M | $25.1M | −$1.5M | -6% |
| Depreciation & amortization | $292K | $404K | −$112K | -28% |
| Share-based compensation | $3.0M | $2.7M | $365K | +14% |
| Working capital & other | $18.7M | −$7.9M | $26.6M | — |
| Cash used in operations | $1.6M | $29.9M | −$28.4M | -95% |
| Net loss absorbed | $23.6M | $25.1M | −$1.5M | -6% |
Questions
How much did C4 Therapeutics's revenue grow quarter over quarter in Q2 2026?
C4 Therapeutics's revenue rose $489K (+8%) from $6.2M in Q1 2026 to $6.6M in Q2 2026.